Effects on various gluco-metabolic and lipid parameters of lobeglitazone as compared with placebo from baseline to 24 weeks.

HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein;* Outlier values are removed.†P-values are for ANCOVA after adjusting baseline values. Multiple comparison by the Bonferroni was applied to analyses the primary endpoint (HbA1c).a,b,cSignificant changes from baseline to week 24 are indicated by a Pb Pc PLast-observation-carried-forward analysis, the intention-to-treat population.